[1]司新鹏.索拉非尼对人肺癌细胞株A549增殖的影响及其机制的研究[J].医学信息,2018,31(17):8-13.[doi:10.3969/j.issn.1006-1959.2018.17.003]
　SI Xin-peng.Effect of Sorafenib on Proliferation of Human Lung Cancer Cell Line A549 and its Mechanism[J].Journal of Medical Information,2018,31(17):8-13.[doi:10.3969/j.issn.1006-1959.2018.17.003]
点击复制

索拉非尼对人肺癌细胞株A549增殖的影响及其机制的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年17期
页码:
8-13
栏目:
出版日期:
2018-09-01

文章信息/Info

Title:
Effect of Sorafenib on Proliferation of Human Lung Cancer Cell Line A549 and its Mechanism
文章编号:
1006-1959（2018）17-0008-06
作者:
司新鹏
山东省泰安市中心医院呼吸内科，山东 泰安 271000
Author(s):
SI Xin-peng
Department of Respiratory Medicine,Tai'an Central Hospital,Tai'an 271000,Shandong,China
关键词:
索拉非尼; A549肺癌细胞; VEGFR-2; VEGFR-3; P-VEGFR-2; P-VEGFR-3
Keywords:
Key words：Sorafenib; A549 lung cancer cells; VEGFR-2; VEGFR-3; P-VEGFR-2; P-VEGFR-3
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.17.003
文献标志码:
A
摘要:
目的 以人肺癌细胞株A549为研究对象，观察不同浓度/时间下索拉尼非对人肺癌细胞A549的增殖及其对VEGFR-2、VEGFR-3、P-VEGFR-2及P-VEGFR-3表达的影响。方法 不同浓度的索拉非尼（1.5 μmol/L、3 μmol/L、6 μmol/L、12 μmol/L）分别与A549细胞体外培养24 h、48 h、72 h后采用四甲基偶氮唑蓝比色法测定细胞生长抑制率。采用RT-PCR法测定不同药物浓度/时间下肺癌细胞株A549中VEGFR-2mRNA、VEGFR-3mRNA的表达变化，用Western Blot法测定P-VEGFR-2及P-VEGFR-3的表达。结果 在外源性药物索拉非尼的刺激下，肺癌细胞A549的生长受到抑制，索拉非尼的浓度越高，作用时间越长，抑制率越大，提示呈现时间和浓度依赖性（P＜0.05）。以终浓度为1.5 μmol/L、3 μmol/L、6 μmol/L、12 μmol/L的索拉非尼加入实验组，在不同的作用时间（24 h、48 h、72 h）下，实验组与对照组比较VEGFR-2mRNA及VEGFR-3mRNA的表达无明显变化（P＞0.05）。P-VEGFR-2及P-VEGFR-3的表达与对照组比较呈现下降趋势（P＜0.05），呈浓度依赖性。结论 索拉非尼能抑制A549肺癌细胞的生长，呈现时间和浓度依赖性。索拉非尼能抑制A549肺癌细胞的生长，其机制之一可能与其抑制P-VEGFR-2及P-VEGFR-3的表达有关。
Abstract:
Abstract：Objective The proliferation of human lung cancer cell line A549 and its effects on the expression of VEGFR-2,VEGFR-3, P-VEGFR-2 and P-VEGFR-3 were observed at different concentrations/time.Methods Different concentrations of sorafenib(1.5μmol/L,3μmol/L,6μmol/L,12μmol/L)were cultured with A549 cells for 24,48 and 72h respectively.The inhibition rate of cell growth was determined by tetramethylazo blue colorimetry.The expression of VEGFR-2 mRNA and VEGFR-3 mRNA in lung cancer cell line A549 was detected by RT-PCR and the expression of P-VEGFR-2 and P-VEGFR-3 was detected by Western Blot.Results Under the stimulation of the exogenous drug sorafenib,the growth of lung cancer cell A549 was inhibited.The higher the concentration of sorafenib, the longer the duration of action,the greater the inhibition rate, suggesting time- and concentration-dependent(P<0.05). Sorafenib at a final concentration of 1.5μmol/L,3μmol/L,6μmol/L,and 12μmol/L was added to the experimental group at different time(24h,48h,72h),there was no significant difference in the expression of VEGFR-2 mRNA and VEGFR-3 mRNA between the experimental group and the control group(P>0.05).The expression of P-VEGFR-2 and P-VEGFR-3 decreased in a concentration-dependent manner compared with the control group(P<0.05).Conclusion Sorafenib can inhibit the growth of A549 lung cancer cells in a time-and concentration-dependent manner.Sorafenib can inhibit the growth of A549 lung cancer cells,and one of its mechanisms may be related to its inhibition of P-VEGFR-2 and P-VEGFR-3 expression.

参考文献/References:

[1]Strumberg D.Preclinical and clinical development of the oral multikiase inhibitor sorafenib in cancer treatment[J].Drugs Today(Barc),2012,41(12):773-784. [2]Beeram M,Patnaik A,Rowinsky EK.Regulation of c-Raf-1:therapeu- utic implications[J].Clin Adv Hematol Oncol,2014,1(8):476-481. [3]Bos JL.Ras oncogenes in human cancer:a review[J].Cancer Res,2009,49(17):4682-4689. [4]Garnett MJ,Marais R.Guilty as charged:B-RAF is a human oncogene[J].Cancer Cell,2004,6(4):313-319. [5]Beeram M,Patnaik A,Rowinsky EK.Raf:a strategic target for therapeutic development against cancer[J].J Clin Oncol,2012,23(27):6771-6790. [6]Mosmann T.Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytoxicity assay[J].J Immunol Methods,2005(1-2):55-63. [7]Mendel DB,Laird AD,Xin X,et al.In vivo antitumor activity of SU11248,a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletdrived growth factor receptors:determination of a pharmacokinetic pharmacodynamic relationship[J].Clin Cancer Res,2013(1):327-337. [8]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF MEK ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis[J].Cancer Res,2014,65(19):7099-7109. [9]Lyons JF,Wilhelm S,Hibner B,et al.Discovery of a novel Raf kinase inhibitor[J].Endocr Relat Cancer,2013,8(3):219-225.

更新日期/Last Update: 2018-09-01